Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.10.4451

Health-Related Quality of Life of Patients with Intermediate Hepatocellular Carcinoma after Liver Resection or Transcatheter Arterial Chemoembolization  

Xie, ZR (Liver Surgery, West China Hospital, Sichuan University)
Luo, YL (Liver Surgery, West China Hospital, Sichuan University)
Xiao, FM (Liver Surgery, West China Hospital, Sichuan University)
Liu, Q (Liver Surgery, West China Hospital, Sichuan University)
Ma, Y (Liver Surgery, West China Hospital, Sichuan University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.10, 2015 , pp. 4451-4456 More about this Journal
Abstract
Background: The aim of our present study was to compare quality of life (QoL) between intermediate-stage (BCLC-B) HCC patients who had undergone either liver resection or transcatheter arterial chemoembolization (TACE). Materials and Methods: A total of 102 intermediate-stage HCC patients participated in our study, including 58 who had undergone liver resection and 44 who had undergone TACE. Baseline demographic characteristics, tumor characteristics, and long-term outcomes, such as tumor recurrence, were compared and analyzed. QoL was assessed using the Short Form (SF)-36 health survey questionnaire with the mental and physical component scales (SF-36 MCS and PCS). This questionnaire was filled out at HCC diagnosis and 1, 3, 6, 12, 24 months after surgery. Results: For the preoperative QoL evaluation, the 8 domains related to QoL were comparable between the two groups. The PCS and MCS scores were significantly decreased in both the TACE and resection groups at1 month after surgery, and this decrease was greater in the resection group. These scores were significantly lower in the resection group compared with the TACE group (P<0.05). However, these differences disappeared at 3 and 6 months following surgery. One year after surgery, the resection group showed much higher PCS scores than the TACE patients (P=0.018), and at 2 years after surgery, the PCS and MCS scores for the resection group were significantly higher than those for the TACE group (P<0.05). Eleven patients (19.0%) in the resection group and 17 (38.6%) in the TACE group suffered HCC recurrence (P<0.05). Univariate and multivariate analyses indicated that tumor recurrence (HR=1.211, 95%CI: 1.086-1.415, P=0.012) was a significant risk factor for poorpostoperative QoL in the HCC patients.Conclusions: Due to its effects on reducing HCC recurrence and improving long-term QoL, liver resection should be the first choice for the treatment of patients with intermediate-stage HCC.
Keywords
Hepatocellular carcinoma; quality of life; liver resection; transcatheter arterial chemoembolization;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Jemal A, Bray F, Center MM, et al (2011). CA Cancer J Clin, 61, 69-90.   DOI
2 Maluccio M, Covey A (2012). Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin, 62, 394-9.   DOI
3 Bruix J, Gores GJ, Mazzaferro V (2014). Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 63, 844-55.   DOI
4 Zuo CH, Xia M, Liu JS, et al (2015). Transcatheter arterial chemoembolization combined with interferon-alpha is safe and effective for patients with hepatocellular carcinoma after curative resection. Asian Pac J Cancer Prev, 16, 245-51.   DOI
5 Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatol, 53, 1020-2.   DOI
6 Xu C, Lv PH, Huang XE, et al (2014). Safety and efficacy of sequential transcatheter arterial chemoembolization and portal vein embolization prior to major hepatectomy for patients with HCC. Asian Pac J Cancer Prev, 15, 703-6.   DOI   ScienceOn
7 Marrero JA, Fontana RJ, Barrat A, et al (2005). Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatol, 41, 707-16.   DOI
8 Zhong JH, Ke Y, Gong WF, et al (2014). Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg, 260, 329-40.   DOI
9 Jianyong L, Lunan Y, Wentao W, et al (2014). Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection? Medicine (Baltimore), 93, 180.   DOI
10 Slevin ML (1992). Quality of life: philosophical question or clinical reality? BMJ, 305, 466-9.   DOI
11 Han KT, Park EC, Kim SJ, et al (2014). Factors affecting the quality of life of Korean cancer survivors who return to the workplace. Asian Pac J Cancer Prev, 15, 8783-8.   DOI
12 Langenhoff BS, Krabbe PF, Wobbes T, et al (2001). Quality of life as an outcome measure in surgical oncology. Br J Surg, 88, 643-52.   DOI
13 Scurtu R, Groza N, Otel O, et al (2005). Quality of life in patients with esophagojejunal anastomosis after total gastrectomy for cancer. Rom J Gastroenterol, 14, 367-72.
14 Diouf M, Bonnetain F, Barbare JC, et al (2015). Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. Oncologist, 20, 62-71.   DOI
15 Diouf M, Filleron T, Barbare JC, et al (2013). The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol, 58, 509-21.   DOI
16 Yeo W, Mo FK, Koh J, et al (2006). Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol, 17, 1083-9.   DOI
17 Gandhi S, Khubchandani S, Iyer R (2014). Quality of life and hepatocellular carcinoma. J Gastrointest Oncol, 5, 296-317.
18 Fan SY, Eiser C, Ho MC (2010). Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroenterol Hepatol, 8, 559-64.   DOI
19 Bruns H, Kratschmer K, Hinz U, et al (2010). Quality of life after curative liver resection: a single center analysis. World J Gastroenterol, 16, 2388-95.   DOI
20 Mise Y, Satou S, Ishizawa T, et al (2014). Impact of surgery on quality of life in patients with hepatocellular carcinoma. World J Surg, 38, 958-67.   DOI
21 Xing M, Webber G, Prajapati HJ, et al (2015). Preservation of quality of life with doxorubicin drug eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: longitudinal prospective study. J Gastroenterol Hepatol, [Epub ahead of print].
22 Wang YB, Chen MH, Yan K, et al (2007). Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Qual Life Res, 16, 389-97.   DOI
23 Toro A, Pulvirenti E, Palermo F, et al (2012). Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment. Surg Oncol, 21, 23-30.   DOI
24 Li L, Wang H, Shen Y (2002). Development and psychometric tests of a Chinese version of the SF-36 Health Survey Scales. Zhonghua yu fang yi xue za zhi, 36, 109-13.
25 Jin S, Yan L, Li B, et al (2010). Quality of life and psychologic distress of recipients after adult living-donor liver transplantation (LDLT)-A study from mainland China. Transplant Proc, 42, 2611-6.   DOI
26 Zhang T, Zeng Y, Huang J, et al (2014). Combined resection with radiofrequency ablation for bilobar hepatocellular carcinoma: a single-center experience. J Surg Res, 191, 370-8.   DOI
27 Jiang L, Lei JY, Wang WT, et al (2014). Immediate radical therapy or conservative treatments when meeting the Milan criteria for advanced HCC patients after successful TACE. J Gastrointest Surg, 18, 1125-30.   DOI
28 Schipper H, Clinch J, McMurray A, et al (1984). Measuring the quality of life of cancer patients: the functional living indexcancer: development and validation. J Clin Oncol, 2, 472-83.   DOI
29 Mancuso A, Mazzola A, Cabibbo G, et al (2015). Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis. Dig Liver Dis, 47, 324-30   DOI
30 Berk V, Kaplan MA, Tonyali O, et al (2013). Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. Asian Pac J Cancer Prev, 14, 7367-9.   DOI   ScienceOn
31 Steel JL, Geller DA, Robinson TL, et al (2014). Health-related quality of life as a prognostic factor in patients with advanced cancer. Cancer, 120, 3717-21.   DOI
32 Martin RC, Eid S, Scoggins CR, et al (2007). Health-related quality of life: return to baseline after major and minor liver resection. Surgery, 142, 676-84.   DOI
33 Poon RT, Fan ST, Yu WC, et al (2001). A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. Arch Surg, 136, 693-9.   DOI